How should diabetic nephropathy be treated, including antihypertensive therapy (ACE inhibitor or ARB), SGLT2 inhibitor use, glycemic control, dietary sodium and protein restriction, lipid management, and additional agents for persistent albuminuria?

Treatment of Diabetic Nephropathy

All patients with diabetic nephropathy should receive a comprehensive, multi-drug regimen including an ACE inhibitor or ARB (titrated to maximum tolerated dose), an SGLT2 inhibitor (initiated when eGFR ≥20 ml/min/1.73 m²), a statin, and for type 2 diabetes with persistent albuminuria ≥30 mg/g despite these therapies, add the nonsteroidal mineralocorticoid receptor antagonist finerenone. 1, 2

Foundation Therapy (All Patients)

Renin-Angiotensin System Blockade

• ACE inhibitor or ARB is mandatory for all patients with diabetic nephropathy who have hypertension and albuminuria 1, 2
• Titrate to the maximum approved dose that is tolerated, not just to blood pressure targets 1
• For patients with albuminuria but normal blood pressure, ACE inhibitor or ARB may still be considered 1
• Monitor creatinine, potassium, and blood pressure within 2-4 weeks of initiation or dose increase 1
• Continue therapy unless creatinine rises >30% within 4 weeks of starting or dose escalation 1
• Never combine ACE inhibitor with ARB - this increases adverse events (hyperkalemia, AKI) without additional benefit 2

SGLT2 Inhibitors (Type 2 Diabetes)

• Initiate when eGFR ≥20 ml/min/1.73 m² and continue until dialysis or transplantation 1, 2
• These provide kidney and cardiovascular protection independent of glucose-lowering effects 3
• Benefits persist even as eGFR declines below 20 ml/min/1.73 m² 4
• Continue SGLT2 inhibitors once started, even if eGFR falls below initiation threshold 1, 4

Lipid Management

• Statin therapy is recommended for ALL patients with diabetic nephropathy (both type 1 and type 2 diabetes) 1, 2
• Use moderate intensity for primary prevention of atherosclerotic cardiovascular disease
• Use high intensity for patients with established cardiovascular disease or multiple risk factors 2

Glycemic Control Strategy

Type 2 Diabetes

• First-line: Metformin + SGLT2 inhibitor 1
• Metformin can be used when eGFR ≥30 ml/min/1.73 m²; reduce dose to 1000 mg daily when eGFR 30-44 ml/min/1.73 m² 2
• Add GLP-1 receptor agonist if glycemic targets not met with metformin and SGLT2 inhibitor, or if these agents cannot be used 1, 2
• Choose GLP-1 RA with proven cardiovascular benefit 2

Type 1 Diabetes

• Insulin remains the cornerstone of therapy 1
• ACE inhibitor/ARB and statin therapy as above

Additional Risk-Based Therapy

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone)

Add finerenone for patients with type 2 diabetes who have persistent albuminuria ≥30 mg/g despite standard therapy 1, 2

Initiation criteria:

• eGFR ≥25 ml/min/1.73 m² 2
• Serum potassium ≤5.0 mmol/L 2
• Already on ACE inhibitor or ARB, SGLT2 inhibitor, and statin

Dosing algorithm:

• Start 10 mg daily if eGFR 25-60 ml/min/1.73 m² 2
• Start 20 mg daily if eGFR >60 ml/min/1.73 m² 2
• Check potassium 4 weeks after starting or dose change 2
• Uptitrate to 20 mg daily if potassium <4.8 mmol/L 2
• Continue if potassium ≤5.5 mmol/L 2
• Withhold if potassium >5.5 mmol/L; restart at 10 mg when potassium ≤5.0 mmol/L 2

This represents the most significant advance beyond traditional ACE inhibitor/ARB therapy, with proven kidney and cardiovascular benefits in patients with residual albuminuria 1, 2.

Blood Pressure Management

• Target individualized blood pressure goals using additional agents as needed 1
• After ACE inhibitor or ARB, add dihydropyridine calcium channel blocker and/or diuretic to reach targets 1
• All three classes (ACE inhibitor/ARB, calcium channel blocker, diuretic) are often needed 1
• Steroidal mineralocorticoid antagonists (spironolactone) can be used for resistant hypertension if potassium is normal 1, 5

Lifestyle Interventions

Dietary Modifications

• Sodium restriction to slow CKD progression and reduce cardiovascular risk 6, 7
• Protein restriction with preference for plant-based protein sources 6
• Weight reduction if overweight 1, 7

Other Measures

• Smoking cessation 1, 7
• Increased physical activity 7

Critical Monitoring Parameters

Hyperkalemia Management

Do not immediately discontinue ACE inhibitor/ARB or finerenone for hyperkalemia 1

• First implement measures to reduce potassium levels (dietary restriction, diuretics, potassium binders) 1
• Only reduce dose or discontinue if potassium cannot be controlled with these measures 1

Creatinine Monitoring

• Expect small initial decline in eGFR with ACE inhibitor/ARB or SGLT2 inhibitor initiation 1
• This hemodynamic effect is expected and beneficial long-term 1
• Only discontinue ACE inhibitor/ARB if creatinine rises >30% within 4 weeks 1

Special Considerations

Women of Childbearing Age

• Advise contraception while on ACE inhibitor or ARB 1
• Discontinue immediately if pregnancy is planned or occurs 1

Cardiovascular Disease

• Add antiplatelet therapy (aspirin) for secondary prevention in established cardiovascular disease 1
• Consider for primary prevention in high atherosclerotic cardiovascular disease risk 1
• Consider ezetimibe, PCSK9 inhibitor, or icosapent ethyl based on lipid levels and cardiovascular risk 1

This evidence-based approach prioritizes the 2022 KDIGO guidelines 1, 2 which represent the most current, comprehensive, and authoritative recommendations for diabetic nephropathy management, emphasizing that treatment must extend far beyond glucose control alone to address the multifactorial nature of kidney disease progression and cardiovascular risk.